NDANASALSPRAY, METERED
Approved
Aug 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
MIACALCIN (calcitonin salmon) by Viatris (2) is agonist. Approved for symptomatic paget's disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase, urinary hydroxyproline excretion, postmenopausal osteoporosis in women greater than 5 years postmenopause and 2 more indications. First approved in 1995.
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIACALCIN (calcitonin salmon) is a nasal spray calcitonin agonist that acts on bone, kidney, and gastrointestinal tissues to regulate calcium metabolism. It is indicated for symptomatic Paget's disease of bone and postmenopausal osteoporosis in women >5 years postmenopause. Calcitonin salmon is more potent per mg and has longer duration of action than mammalian calcitonins, working through calcitonin receptors on osteoclasts and osteoblasts.
$0.837MPart D
LOE ApproachingDeclining
With minimal Part D claims and approaching loss of exclusivity, the MIACALCIN team is likely small and focused on managed decline rather than growth initiatives.
Mechanism of Action
agonist. Calcitonin salmon acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognized. Calcitonin salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer…
Worked on MIACALCIN at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.